HC Wainwright Issues Positive Forecast for BEAM Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a report issued on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.78) per share for the quarter, up from their previous estimate of ($0.94). HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics' Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.75) EPS, FY2028 earnings at ($1.77) EPS and FY2029 earnings at ($1.34) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.13). The firm had revenue of $7.47 million during the quarter, compared to analyst estimates of $14.69 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.21) earnings per share.

A number of other equities research analysts have also issued reports on BEAM. Royal Bank of Canada increased their target price on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 26th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company decreased their price objective on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Bank of America upgraded Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 target price on the stock in a research report on Friday, March 28th. Finally, Scotiabank raised Beam Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $40.00 price target on the stock in a research report on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $48.75.

Beam Therapeutics Stock Performance

Shares of BEAM stock traded down $0.81 on Monday, hitting $17.24. 1,662,661 shares of the stock traded hands, compared to its average volume of 1,436,748. The firm's 50-day moving average price is $19.73 and its two-hundred day moving average price is $24.29. The stock has a market capitalization of $1.73 billion, a PE ratio of -9.80 and a beta of 2.35. Beam Therapeutics has a twelve month low of $13.53 and a twelve month high of $35.25.

Institutional Trading of Beam Therapeutics

Large investors have recently bought and sold shares of the company. Wealthfront Advisers LLC acquired a new stake in Beam Therapeutics in the fourth quarter valued at $41,000. GF Fund Management CO. LTD. acquired a new position in Beam Therapeutics during the fourth quarter worth about $43,000. CWM LLC raised its position in Beam Therapeutics by 79.8% during the first quarter. CWM LLC now owns 2,684 shares of the company's stock worth $52,000 after acquiring an additional 1,191 shares during the last quarter. Sterling Capital Management LLC raised its position in Beam Therapeutics by 816.0% during the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock worth $60,000 after acquiring an additional 2,146 shares during the last quarter. Finally, Amalgamated Bank raised its position in Beam Therapeutics by 20.4% during the first quarter. Amalgamated Bank now owns 3,153 shares of the company's stock worth $62,000 after acquiring an additional 534 shares during the last quarter. Institutional investors and hedge funds own 99.68% of the company's stock.

Insider Transactions at Beam Therapeutics

In other news, CEO John M. Evans sold 30,663 shares of Beam Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $562,666.05. Following the completion of the sale, the chief executive officer now directly owns 986,249 shares in the company, valued at approximately $18,097,669.15. This trade represents a 3.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Giuseppe Ciaramella sold 7,434 shares of Beam Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total transaction of $136,413.90. Following the sale, the president now owns 190,216 shares of the company's stock, valued at approximately $3,490,463.60. The trade was a 3.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,771 shares of company stock valued at $803,198 in the last ninety days. 4.20% of the stock is currently owned by company insiders.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.